GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why

By Yahoo! Finance | Nov 14, 2024 at 02:50 PM EST

GSK plc announced positive interim results from the DREAMM-7 trial for belantamab mafodotin in combination with BorDex for multiple myeloma. The study showed improved overall survival compared to standard treatment. Plans for further studies and filings in multiple countries are underway.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.